Anti-hepatitis B virus antibody and application thereof

By introducing enhanced binding mutations into the Fc domain of the antibody, the problem of low HBV virus clearance efficiency in the prior art is solved, more efficient HBsAg clearance and antibody stability are achieved, and an effective hepatitis B virus treatment plan is provided.

CN118909102APending Publication Date: 2024-11-08XIAMEN UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411144130.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art cannot effectively remove HBV viruses, especially HBsAg, when treating chronic HBV infection, and the existing application of hepatitis B immunoglobulin has problems with insufficient titer, high price, unstable nature and safety.

Method used

An antibody against hepatitis B virus was developed, with its heavy chains CDR1-3 having a specific amino acid sequence, and introduced mutations to enhance binding to hFcγRs and hFcRn in the Fc domain, improving the clearance efficiency of HBsAg and prolonging the half-life.

Benefits of technology

It significantly improves the clearance efficiency of HBsAg and the stability of the antigen binding domain, extends the half-life of the antibody, enhances the interaction between Fc-hFcγRs and Fc-hFcRn, and provides a more effective hepatitis B virus treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention relates to an antibody against hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the antibody, and a pharmaceutical composition comprising the antibody. The humanized anti-HBsAg antibody disclosed by the invention can be combined with HBsAg with high affinity, has enhanced capability of combining with hFc [gamma] Rs and hFcRn, and has remarkably enhanced antigen removal effect and prolonged half-life period.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of antibody technology, in particular to anti-hepatitis B virus antibodies and uses thereof. Background Art

[0002] Hepatitis B virus infection, especially chronic HBV infection, is one of the most important public health problems in the world. Chronic HBV infection can lead to a series of liver diseases such as chronic hepatitis B (CHB), liver cirrhosis (LC) and primary hepatocellular carcinoma (HCC).

[0003] The current therapeutic drugs for chronic HBV infection can be mainly divided into interferons (IFNs) and nucleoside / nucleotide analogs. For HBV infected people (such as CHB patients), the above drugs alone or in combination can effectively inhibit viral replication in the body and significantly reduce HBV DNA levels. However, the above drugs alone or in combination cannot completely eliminate the HBV virus in the infected person, and the response rate of HBsAg negative conversion or HBsAg seroconversion (a sign of complete elimination of HBV virus in the infected person) is usually less than 5%.

[0004] The development of new drugs for the treatment of chronic HBV infection based on immunological methods is one of the important research directions in this field. At present, anti-HBs polyclonal antibodies purified from the serum / plasma of preventive hepatitis B vaccine responders or HBV infection recoverers, namely high-titer hepatitis B immunoglobulin (HBIG), have been widely used to block mother-to-child vertical transmission of HBV, prevent HBV reinfection after liver transplantation in chronic HBV infected people, and prevent infection in people accidentally exposed to HBV. However, there is no obvious therapeutic effect when HBIG is directly used for the treatment of HBV infected people (such as CHB patients), and it has many limitations such as limited sources of high-titer plasma, high price, unstable nature, and potential safety issues.

[0005] Therefore, it is urgent and necessary to develop innovative treatments and drugs for HBV-infected patients that can more effectively eliminate HBV virus, especially HBsAg. Summary of the invention

[0006] In view of this, the technical problem to be solved by the present invention is to provide hepatitis B virus antibodies and uses thereof.

[0007] The heavy chain CDR1 to 3 of the anti-HBV antibody provided by the present invention have the amino acid sequences shown in SEQ ID NOs: 6 to 8, respectively.

[0008] Alternatively, the CDR region has a sequence in which one or more amino acids are substituted, deleted, added and / or replaced based on the amino acid sequence as described above; or has a sequence with an identity of more than 80% to the amino acid sequence as described above. The identity of more than 80% refers to an identity of 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100%.

[0009] In the anti-HBV antibody provided by the present invention, the Fc domain comprises a first mutation that enhances binding to hFcγRs and a second mutation that enhances binding to hFcRn.

[0010] Preferably, the first mutation also enhances binding to hFcγRIIa and / or hFcγRIIIa;

[0011] Preferably, the first mutation is selected from the following mutations according to EU numbering: S239D / A330L / I332E, G236A / S239D / A330L / I332E.

[0012] More preferably, the first mutation is G236A / S239D / A330L / I332E.

[0013] Preferably, the second mutation is selected from the following mutations according to EU numbering: M428L / N434S, T307Q / N434S.

[0014] More preferably, the second mutation is T307Q / N434S.

[0015] In some embodiments, the first mutation is S239D / A330L / I332E, and the second mutation is T307Q / N434S.

[0016] In some specific embodiments, the Fc domain is IgG, such as IgG1, IgG2, IgG3, or IgG4; preferably, the Fc domain is human IgG1.

[0017] In some embodiments, the heavy chain constant region of the anti-hepatitis B virus antibody provided by the present invention has the amino acid sequence shown in any one of SEQ ID NO:14.

[0018] Alternatively, the constant region has a sequence in which one or more amino acids are substituted, deleted, added and / or replaced based on the amino acid sequence shown above; or has a sequence with an identity of more than 80% with the amino acid sequence shown in any of the above items.

[0019] The present invention can significantly improve HBsAg clearance efficiency and prolong half-life by simultaneously introducing mutations that enhance binding to hFcγRs and hFcRn into the Fc region of the antibody, thereby obtaining a hepatitis B therapeutic antibody with a humanized antigen binding domain, enhanced Fc-hFcγRs interaction and enhanced Fc-hFcRn interaction.

[0020] In some embodiments, the amino acid sequence of the heavy chain constant region of the anti-hepatitis B virus antibody is: EPKSCDKTHTCPPCPAPELLX1GPX2VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLX3VLHQDWLNGKEYKCKVSNKALPX4PX5EKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVX6HEALHX7HYTQKSLSLSPGK (SEQ ID NO: 14), wherein X1 is G or A, X2 is S or D, X3 is T or Q, X4 is A or L, X5 is I or E, X6 is L or M, and X7 is N or S.

[0021] In some specific embodiments, the amino acid sequence of the heavy chain constant region of the anti-hepatitis B virus antibody has an amino acid sequence as shown in any one of SEQ ID NOs: 9 to 13. That is, the amino acid sequence of the heavy chain constant region of the anti-hepatitis B virus antibody is as shown in SEQ ID NO: 9, as shown in SEQ ID NO: 10, or as shown in SEQ ID NO: 11, or as shown in SEQ ID NO: 12, or as shown in SEQ ID NO: 13.

[0022] In some embodiments, the amino acid sequences of the heavy chain CDR1-3 of the anti-hepatitis B virus antibody are: AYAMG (SEQ ID NO: 6), GISWTTSSAYYTDSVKG (SEQ ID NO: 7) and RVSDTVGFGS (SEQ ID NO: 8).

[0023] In some specific embodiments,

[0024] For example,

[0025] The amino acid sequences of the heavy chain CDR1 to 3 of the anti-HBV antibody are shown in SEQ ID NOs: 6 to 8, respectively, and the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO: 9.

[0026] The amino acid sequences of the heavy chain CDR1 to 3 of the anti-HBV antibody are shown in SEQ ID NOs: 6 to 8, respectively, and the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO: 10.

[0027] Or the amino acid sequences of the heavy chain CDR1 to 3 of the anti-hepatitis B virus antibody are shown in SEQ ID NOs: 6 to 8, and the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO: 11.

[0028] Or the amino acid sequences of the heavy chain CDR1 to 3 of the anti-hepatitis B virus antibody are shown in SEQ ID NOs: 6 to 8, and the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO: 12.

[0029] Or the amino acid sequences of the heavy chain CDR1 to 3 of the anti-hepatitis B virus antibody are shown in SEQ ID NOs: 6 to 8, and the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO: 13.

[0030] The anti-HBV heavy chain FR1 to FR4 provided by the present invention have the amino acid sequences shown in SEQ ID NOs: 2 to 5, respectively.

[0031] Alternatively, the FR region has a sequence in which one or more amino acids are substituted, deleted, added and / or replaced based on the amino acid sequence shown above; or has a sequence with an identity of more than 80% with the amino acid sequence shown in any of the above items.

[0032] In some embodiments, the amino acid sequences of the heavy chain FR1-4 of the anti-hepatitis B virus antibody are: EVQLVE SGGGLVQPGGSLRLSCAASGGTIS (SEQ ID NO: 2), WFRQAPGKDREFVA (SEQ ID NO: 3), RFTISRDFAKNTVYLQMNSLKPEDTAVYYCND (SEQ ID NO: 4) and WGQGTL VTVSS (SEQ ID NO: 5).

[0033] In some specific embodiments, the antigen binding domain comprises: a heavy chain variable region (VHH) comprising the sequence shown in SEQ ID NO: 1 or a sequence having at least 80% identity thereto.

[0034] As a feasible example, the amino acid sequence of the heavy chain variable region of the anti-hepatitis B virus antibody is shown in SEQ ID NO: 1; the amino acid sequence of its constant region is shown in SEQ ID NO: 9.

[0035] In another feasible case, the amino acid sequence of the heavy chain variable region of the anti-hepatitis B virus antibody is shown in SEQ ID NO: 1; the amino acid sequence of its constant region is shown in SEQ ID NO: 10.

[0036] In another feasible case, the amino acid sequence of the heavy chain variable region of the anti-hepatitis B virus antibody is shown in SEQ ID NO: 1; the amino acid sequence of its constant region is shown in SEQ ID NO: 11.

[0037] In another feasible case, the amino acid sequence of the heavy chain variable region of the anti-hepatitis B virus antibody is shown in SEQ ID NO: 1; the amino acid sequence of its constant region is shown in SEQ ID NO: 12.

[0038] In another feasible case, the amino acid sequence of the heavy chain variable region of the anti-hepatitis B virus antibody is shown in SEQ ID NO:1; the amino acid sequence of its constant region is shown in SEQ ID NO:13.

[0039] Furthermore, the present invention provides at least one of the following biomaterials:

[0040] a), a nucleic acid encoding the antibody as described above;

[0041] b), an expression unit comprising a promoter and the nucleic acid described in a);

[0042] c) a plasmid vector containing the nucleic acid described in a) or the expression unit described in b);

[0043] d) a host, into whose genome the nucleic acid described in a) or the expression unit described in b) is integrated, or transformed or transfected with the plasmid vector described in c);

[0044] e), a labeled antibody, which comprises the above-mentioned antibody and a labeling substance;

[0045] f), a conjugate comprising the above-mentioned antibody and a medium;

[0046] g) multispecific antibodies, which comprise the above-mentioned antibodies and fragments that specifically bind to other targets;

[0047] h) Antibody derivatives, which include the antibodies as mentioned above and drugs for preventing and treating hepatitis B.

[0048] In the present invention, the nucleic acid is an isolated nucleic acid molecule, which comprises a nucleic acid encoding a CDR region in an antibody as described above, a nucleic acid encoding a variable region in an antibody as described above, a nucleic acid encoding a heavy chain in an antibody as described above, and / or a nucleic acid encoding a light chain in an antibody as described above. In certain embodiments, the nucleic acid molecule comprises a first nucleotide sequence encoding a heavy chain of an antibody of the present invention, and a second nucleotide sequence encoding a light chain of an antibody of the present invention. The first nucleotide sequence and the second nucleotide sequence are on the same or different isolated nucleic acid molecules.

[0049] In the present invention, the expression unit includes a promoter and the aforementioned nucleic acid, and further includes a terminator, an enhancer or a transposon.

[0050] In some embodiments, the promoter is a eukaryotic promoter or a prokaryotic promoter, which is not limited in the present invention. For example, the promoter is a CMV promoter, a CAG promoter, an EF1a promoter, a PGK promoter, a U6 and H1 promoter, an EFS promoter, a CBh promoter, a SFFV promoter, an MSCV promoter, a SV40 promoter, a UBC promoter, or a TRE promoter. The terminator is selected from a T7 phage terminator, a TO phage terminator, a λ phage terminator, a SV40 terminator, a CMV terminator, a rrnB terminator, a bGH terminator, a hGH terminator, or a rbGlob terminator.

[0051] In the present invention, the plasmid vector (e.g., cloning vector or expression vector) comprises the isolated nucleic acid of the present invention or the expression unit as described above. In some embodiments, the vector of the present invention is, for example, a plasmid, a cosmid, a phage, etc. In some embodiments, the vector comprises a first nucleotide sequence encoding the heavy chain of an antibody of the present invention, and a second nucleotide sequence encoding the light chain of an antibody of the present invention. The first nucleotide sequence and the second nucleotide sequence are on the same or different vectors.

[0052] In the present invention, the host includes, but is not limited to, prokaryotic cells such as Escherichia coli cells, and eukaryotic cells such as yeast cells, insect cells, plant cells and animal cells (such as mammalian cells, such as mouse cells, human cells, etc.). In certain embodiments, the host cell of the present invention is a mammalian cell.

[0053] In the present invention, the labeling substance in the labeled antibody is a chemical label or a biological label; in some embodiments, the chemical label is a fluorescent indicator, a chemiluminescent indicator, an isotope and / or a colloid indicator; the biological label is biotin, avidin or an enzyme label. In some specific embodiments, the enzyme label is selected from one or more of horseradish peroxidase, alkaline phosphatase, β-galactosidase, peroxidase-antiperoxidase bridge, alkaline phosphatase-anti-alkaline phosphatase bridge, β-galactosidase-anti-β-galactosidase bridge; in some specific embodiments, the fluorescent indicator is selected from AF350, AF488, AF532, AF546, AF555, AF568, AF594, AF633, AF647, AF660, AF680, FITC, TRITC, RB200, phycoerythrin, APC, Cy5, OregonGreen488, Pacific Blue dye, Pacific Orange dye, Texas In some specific embodiments, the chemiluminescent indicator is selected from one or more of acridinium esters, acridinium sulfonamides and their derivatives, luminol, isoluminol, isoluminol isothiocyanate and its derivatives, N-(4-aminobutyl)-N-ethylisoluminol, 4,5-diaminophthalhydrazide or aminobutylethylphthalhydrazide; In some specific embodiments, the isotope is selected from one or more of 125 I. 131 I. 124 I. 3 H. 14 C. 111 In, 89 Zr or 32 P one or more; in some specific embodiments, the colloidal indicator is selected from one or more of colloidal gold, colloidal carbon or colloidal selenium.

[0054] In the present invention, in the conjugate, the medium is selected from colloidal gold, ELISA plate, magnetic beads or latex microspheres; in the present invention, the connection between the antibody and the medium can be via an amide bond or via a streptavidin-biotin system, which is not limited in the present invention.

[0055] In the present invention, the multispecific antibody is a bispecific antibody or a trispecific antibody; for example, the multispecific antibody specifically binds to HBsAg and additionally specifically binds to other targets.

[0056] In the present invention, in the antibody derivative, the antibody as described above is connected to another molecule (e.g., another polypeptide or protein). Generally, the derivatization (e.g., labeling) of the antibody will not adversely affect its binding to HBsAg. Therefore, the antibody of the present invention is also intended to include such derivatized forms. For example, the antibody of the present invention can be functionally connected (by chemical coupling, gene fusion, non-covalent connection or other means) to one or more other molecular groups, such as another antibody (e.g., forming a bispecific antibody), a pharmaceutical agent, and / or a protein or polypeptide (e.g., avidin or polyhistidine tag) that can mediate the binding of the antibody to another molecule. For example, the antibody derivative includes the antibody as described above and a protein drug for preventing and treating hepatitis B.

[0057] Furthermore, the present invention also provides a method for preparing the antibody as described above, which comprises: culturing the host as described above to obtain a culture containing the antibody. The preparation method described in the present invention also includes the steps of extracting and purifying the antibody from the culture. Among them, the construction method of the host as described above comprises obtaining a DNA molecule encoding the heavy chain and light chain genes of the antibody of the present invention by chemical synthesis or PCR amplification. The obtained DNA molecule is inserted into an expression vector, and then transfected to obtain a host cell.

[0058] Furthermore, the present invention also provides the use of at least one of the aforementioned biological materials in the preparation of a product for detecting hepatitis B virus.

[0059] Furthermore, the present invention provides a product for detecting hepatitis B virus, the raw materials for preparing the product include at least one of the aforementioned biological materials and an immunological detection reagent.

[0060] In the present invention, in the product for detecting hepatitis B virus, the antibody as described above is used as a capture antibody or a detection antibody for hepatitis B virus, and the present invention does not limit this. The immunological detection reagent in the product includes but is not limited to a buffer for immunological detection, such as Tris buffer, Tris-HCl buffer, TBS buffer, PBS buffer, dimethyl cacoate buffer, HEPES buffer, citrate buffer or carbonate buffer. The immunological detection reagent also includes a stabilizer, such as BSA, EDTA, trehalose, mannitol, DTT, β-mercaptoethanol, dimethyl sulfoxide, etc. In addition, preservatives such as sodium azide, gentamicin, amphotericin, etc., and surfactants such as Tween and TritonX-100 may also be included.

[0061] Furthermore, the present invention also provides a method for detecting hepatitis B virus, which comprises detecting a sample using the product as described above.

[0062] In the present invention, the detection method adopts an immunological detection method, including but not limited to ELISA, Western blot, magnetic particle chemiluminescence method and / or colloidal gold test strips. The detection principle includes but is not limited to direct detection method, simple detection method, competition method, immunoblotting method, ELISA, double antibody sandwich method.

[0063] In the present invention, the method for detecting hepatitis B virus is for diagnostic purposes or non-diagnostic purposes, which is not limited in the present invention. Taking the detection for diagnostic purposes as an example, it includes detecting samples from organisms, such as blood, saliva, tears, body fluids, hair and / or tissues. Taking the detection for non-diagnostic purposes as an example, it includes detecting samples from non-biological samples. For example, the method includes detecting samples from the environment, and the environmental samples include but are not limited to water bodies, swabs on the surface of supplies, food, medicines, cosmetics or other related products, etc., which is not limited in the present invention.

[0064] Furthermore, the present invention also provides the use of the aforementioned biomaterial in the preparation of products for preventing and treating diseases caused by hepatitis B virus infection.

[0065] The product is used to prevent and / or treat HBV infection or a disease associated with HBV infection (eg, hepatitis B) in a subject (eg, a human), and / or to reduce the serum level of HBV DNA and / or HBsAg in a subject (eg, a human).

[0066] Furthermore, the present invention also provides a product for preventing and treating diseases caused by hepatitis B virus infection, and the raw materials for preparing the product include at least one of the aforementioned biological materials and auxiliary materials.

[0067] In the present invention, the product is a vaccine and / or a drug. The product for preventing and treating diseases caused by hepatitis B virus infection also includes other drugs with activity for preventing and treating diseases caused by hepatitis B virus infection. In certain embodiments, the other drugs with activity for preventing and treating diseases caused by hepatitis B virus infection are drugs for preventing or treating HBV infection or diseases related to HBV infection (e.g., hepatitis B), such as interferon drugs, such as interferon or pegylated interferon.

[0068] In the present invention, the excipients include pharmaceutically or vaccine acceptable carriers and / or excipients. The product of the present invention can be formulated into a dosage form compatible with its intended route of administration. For example, tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injections, sterile powders for injection and concentrated solutions for injection), inhalants, sprays, etc. The preferred dosage form depends on the intended mode of administration and therapeutic use. The antibody or pharmaceutical composition of the present invention should be sterile and stable under production and storage conditions. A preferred dosage form is an injection. Such an injection can be a sterile injection solution. For example, a sterile injection solution can be prepared by the following method: incorporating the necessary dose of active ingredients in an appropriate solvent, and optionally, incorporating other desired ingredients (including but not limited to, pH regulators, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof), followed by filtration and sterilization. In addition, sterile injectable solutions can be prepared as sterile lyophilized powders (e.g., by vacuum drying or freeze drying) for storage and use. Such sterile lyophilized powders can be dispersed in a suitable carrier before use, such as water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), a solution containing a surfactant (e.g., 0.01% polysorbate 20), a pH buffer solution (e.g., phosphate buffer solution), Ringer's solution, and any combination thereof.

[0069] Furthermore, the present invention also provides a method for preventing and treating diseases caused by hepatitis B virus infection, which comprises administering the product of the present invention to a subject.

[0070] In the present invention, the prevention and treatment include prevention and / or treatment, including prevention or treatment of HBV infection or diseases related to HBV infection (such as hepatitis B) in a subject (such as a human), and / or for reducing the serum level of HBV DNA and / or HBsAg in a subject (such as a human). The method comprises administering an effective amount of the antibody or product of the present invention to a subject in need thereof.

[0071] The product of the present invention can be applied by any suitable method known in the art.Preferred routes of administration include intravenous, intraperitoneal, intramuscular, subcutaneous, spinal or other parenteral routes of administration.Parenteral administration refers to the administration mode usually by injection rather than enteral and topical administration, including but not limited to intravenous, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, it can be applied via non-parenteral routes, such as topical, epidermal or mucosal administration routes, such as intranasal, oral, vaginal, rectal, sublingual or local. For many therapeutic uses, preferred routes of administration / modes are parenteral administration (e.g., intravenous injection or push injection, subcutaneous injection, intraperitoneal injection, intramuscular injection). Technicians should understand that routes of administration and / or modes will change according to the intended purpose. In certain embodiments, the antibody or pharmaceutical composition of the present invention is administered by intravenous injection or push injection.

[0072] The antibodies and pharmaceutical compositions provided by the present invention can be used alone or in combination with other pharmaceutically active agents (eg, other antiviral agents, such as interferon drugs, such as interferon or pegylated interferon).

[0073] The antibody or pharmaceutical composition of the present invention can be formulated in dosage unit form for ease of administration. Dosage unit form refers to physically discrete units suitable as single doses for the subject to be treated; each unit contains a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in combination with the required pharmaceutical carrier.

[0074] The subject described herein can be a mammal, such as a human. In certain embodiments, the subject is an HBV infected person, such as a chronic HBV infected person or a chronic hepatitis B patient. In certain embodiments, the subject has been exposed to HBV or is at risk of being exposed to HBV.

[0075] In the present invention, when the product includes other drugs for preventing and / or treating FPV virus infection, two or more drugs can be administered simultaneously or sequentially, and the present invention is not limited to this.

[0076] In the present invention, the product is administered before exposure to the virus, and the duration of the administration in advance is no longer than 10 years, preferably no longer than 5 years, preferably no longer than 3 years, more preferably no longer than 1 year, more preferably no longer than 6 months, more preferably no longer than 3 months; more preferably, no longer than 1 month, more preferably, no longer than 15 days, more preferably, no longer than 7 days. In other feasible cases, the product is administered after exposure to the virus, and the duration after exposure to the virus is no longer than 3 years, preferably no longer than 1 year, more preferably no longer than 6 months, more preferably no longer than 3 months; more preferably, no longer than 1 month, more preferably, no longer than 15 days, more preferably, no longer than 7 days, more preferably, no longer than 3 days, more preferably, no longer than 1 day.

[0077] In the present invention, when the product includes antibodies and other therapeutic agents, the dosing frequency of two or more drugs may be the same or different, and the present invention does not limit this. The dosing interval of two or more drugs is 6 hours, preferably not longer than 5 hours, more preferably not longer than 4 hours, even more preferably not longer than 3 hours, more preferably not longer than 2 hours and most preferably not longer than 1 hour and / or not longer than 6 hours, preferably not longer than 5 hours, more preferably not longer than 4 hours, even more preferably not longer than 3 hours, more preferably not longer than 2 hours and most preferably not longer than 1 hour after the administration of other therapeutic agents.

[0078] The beneficial effects of the invention include at least:

[0079] The present invention provides a hepatitis B therapeutic antibody with a humanized antigen binding domain, enhanced Fc-hFcγRs interaction and enhanced Fc-hFcRn interaction. The antibody of the present invention can reduce the serum level of HBV DNA and / or HBsAg in a subject, and can effectively eliminate HBV and HBV-infected cells in the body. In particular, the antibody of the present invention has a significantly enhanced antigen clearance effect and antigen inhibition time compared to the prior art antibody, and while improving the clinical cure rate, it can also reduce the frequency and dosage of administration, and has great clinical value. BRIEF DESCRIPTION OF THE DRAWINGS

[0080] Figure 1 . Detection of the efficiency of phagocytosis of HBsAg by phagocytes mediated by Fc mutant antibodies in human peripheral blood;

[0081] Figure 2 . Antibody binding test results with membrane expressed hFcRn at pH 6.0;

[0082] Figure 3 .Detection of the efficiency of phagocytosis of HBsAg by phagocytes mediated by Fc double mutant antibodies in human peripheral blood;

[0083] Figure 4 .Schematic diagram of the construction of engineered hepatitis B therapeutic antibody h125s-26-GASDALIE-QS;

[0084] Figure 5 .Engineering hepatitis B therapeutic antibody h125s-26-GASDALIE-QS reducing SDS-PAGE;

[0085] Figure 6 .ELISA binding activity detection of h125s-26-GASDALIE-QS and HBsAg;

[0086] Figure 7 . Detection of serum HBsAg titer after intravenous administration of antibodies in the hFcγRs-Tg mouse model infected with AAV-HBV;

[0087] Figure 8 . Detection of serum antibody concentration in hFcRn-Tg mice after intravenous administration of antibodies. DETAILED DESCRIPTION

[0088] The present invention provides hepatitis B virus antibodies and uses thereof. Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters to achieve the same. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0089] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the cell culture, biochemistry, nucleic acid chemistry, immunology laboratory and other operating procedures used herein are conventional procedures widely used in the corresponding fields. At the same time, in order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.

[0090] As used herein, the term "antibody" refers to a molecule that specifically binds to an antigenic determinant in its broadest sense, and may include various antibody structures, as long as they exhibit the desired antigen-binding activity. Wherein, heavy chain antibodies are composed of heavy chain variable regions (VHH) and heavy chain constant regions (Hinge, CH2, and CH3). VHH is derived from camelids or shark species, has antigen-binding ability, and VHH can be cloned and independently expressed as single-domain antibodies, also known as nanobodies, with a molecular weight of less than 15 kDa. Nanobodies contain three highly variable regions, called complementary determining regions (CDR) and four framework regions (FR), with a typical immunoglobulin folding-like structure. Constant domains do not directly participate in the binding of antibodies to antigens, but exhibit a variety of effector functions, such as mediating the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. Each CDR and FR of VHH is composed of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4, forming an antigen binding domain.

[0091] As used herein, the term "complementarity determining region" or "CDR" refers to the amino acid residues in the variable region of an antibody that are responsible for antigen binding. Each of the variable regions of VHH contains three CDRs, designated as CDR1, CDR2, and CDR3. The precise boundaries of these CDRs can be defined according to various numbering systems known in the art, such as the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 878-883) or the IMGT numbering system (Lefranc et al., Dev. Comparat. Immunol. 27: 55-77, 2003). For a given antibody, a person skilled in the art will easily identify the CDRs defined by each numbering system. Moreover, the correspondence between different numbering systems is well known to those skilled in the art (eg, see Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003).

[0092] In the present invention, the CDRs contained in the antibodies of the present invention can be determined according to various numbering systems known in the art, such as the Kabat, Chothia or IMGT numbering systems. In certain embodiments, the CDRs contained in the antibodies of the present invention are preferably determined by the Kabat numbering system.

[0093] As used herein, the term "framework region" or "FR" residues refers to those amino acid residues in the variable region of an antibody other than the CDR residues as defined above.

[0094] The term "antibody" is not limited to any particular method of producing the antibody. For example, it includes recombinant antibodies, monoclonal antibodies and polyclonal antibodies. The antibody can be an antibody of different isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibody.

[0095] As used herein, the term "heavy chain antibody" means an antibody consisting of a heavy chain variable region (VHH), a hinge region (Hinge) and a heavy chain constant region (CH2 and CH3). The term "nanobody" means that the heavy chain variable region (VHH) of a heavy chain antibody is cloned and independently expressed as a single domain antibody, also known as a nanobody, comprising 3 CDRs regions and 4 FRs. The heavy chain antibody of the present invention may be from a single species, such as camelid species and sharks, or may be a fusion antibody formed by fusing IgG Fc (Hinge-CH2-CH3) of different species with a nanobody. The heavy chain antibody of the present invention comprises two antigen binding sites formed by a nanobody and a constant region fused to human IgG hinge-CH2-CH3. The two antigen binding sites specifically recognize / bind to the same antigen, and two pairs of heavy chain antibodies are linked together by disulfide bonds between the hinges, and the Fc domain composed of CH2-CH3 exhibits a variety of effector functions. As used herein, the expression "humanized heavy chain antibody" refers to a heavy chain antibody molecule whose antigen binding domain has been humanized and whose ELISA HBsAg binding activity is substantially equivalent to that of the parent.

[0096] As used herein, the term "Fc domain" or "Fc region" or "Fc domain" has the meaning commonly understood by those skilled in the art and is used interchangeably, which means the portion of the heavy chain constant region CH2 and CH3. The Fc region of an antibody has a variety of different functions, but is not involved in the binding of an antigen. The "effector functions" mediated by the Fc region include Fc receptor binding; Clq binding and complement dependent cytotoxicity (CDC); antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation, etc. In some embodiments, the Fc region comprises a hinge, CH2, and CH3. When the Fc region comprises a hinge, the hinge regulates the dimerization between two Fc-containing polypeptides. The Fc region can be any antibody heavy chain constant region isotype, such as IgG1, IgG2, IgG3, or IgG4. Amino acid positions within the Fc domain can be numbered according to the EU numbering system of Kabat, see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.

[0097] The Fc domain may include both a native Fc region and a variant Fc region. A native Fc region comprises an amino acid sequence that is consistent with the amino acid sequence of an Fc region found in nature, for example, a native sequence human Fc region comprises a native sequence human IgG1 Fc region (non-A and A allotypes); a native sequence human IgG2 Fc region; a native sequence human IgG3 Fc region; and a native sequence human IgG4 Fc region, as well as naturally occurring variants thereof. A variant Fc region comprises an amino acid sequence that is different from the amino acid sequence of a native sequence Fc region due to at least one amino acid modification. In some embodiments, a variant Fc region may have effector functions (e.g., Fc receptor binding, antibody glycosylation, the number of cysteine ​​residues, effector cell function, or complement function) that are altered compared to a native Fc region. In some embodiments, a variant Fc region may have modifications that promote dimerization. As used herein, a "monomer" of an Fc domain refers to one of the two polypeptides that form a dimeric Fc domain, i.e., a polypeptide comprising a C-terminal constant region in an immunoglobulin heavy chain that is capable of stabilizing its own association.

[0098] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen to which it is directed. The intensity or affinity of the specific binding interaction can be represented by the equilibrium dissociation constant (KD) of the interaction. In the present invention, the term "KD" refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between an antibody and an antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding, and the higher the affinity between an antibody and an antigen. The specific binding properties between two molecules can be measured using methods well known in the art, such as measured in a BIACORE instrument using surface plasmon resonance (SPR).

[0099] As used herein, the expression HBsAg binding activity refers to the K of the antibody of the present invention binding to HBsAg at neutral pH. D Value or EC 50 The K D It can be measured by techniques known in the art, for example, by SPR technology (such as Biacore). In the present invention, the term "EC 50" refers to the antibody-antigen half maximal effect concentration, that is, the antibody concentration required to achieve 50% of the maximum binding effect between a specific antibody and an antigen, which is used to describe the binding ability between the antibody and the antigen. The smaller the EC50, the higher the binding ability between the antibody and the antigen. The antibody-antigen half maximal effect concentration (EC50) can be determined using methods well known in the art, such as using an enzyme-linked immunosorbent assay (ELISA) in which the antibody specifically binds to the antigen by binding to a solid phase carrier. In certain embodiments, the ratio of the HBsAg binding EC50 values ​​of the parent antibody to that of the humanized heavy chain antibody is less than 1.

[0100] As used herein, "neutralizing antibodies" refer to antibodies that can significantly reduce or completely inhibit the virulence of the target virus (e.g., the ability to infect cells). Generally speaking, neutralizing antibodies can recognize and bind to the target virus and prevent the target virus from entering / infecting the cells of the subject. The antibodies of the present invention are neutralizing antibodies.

[0101] However, it should be understood that in the present application, the ability of the antibody to neutralize the virus is not directly equivalent to the ability of the antibody to remove the virus. As used herein, "neutralizing the virus" refers to the process of inhibiting the target virus from entering / infecting the subject's cells, thereby neutralizing the toxicity of the target virus (i.e., significantly reducing or completely inhibiting the toxicity of the target virus). As used herein, "removing the virus" refers to the target virus in the body (whether or not it has infected the cell) being eliminated from the body, so that the body is transformed toward the state before being infected by the virus (for example, the serological test results of the virus are transformed to negative). Therefore, in general, neutralizing antibodies do not necessarily have the ability to remove the virus. However, in the present application, the inventor unexpectedly found that the antibody of the present invention not only has the ability to neutralize HBV, but also has the ability to remove the virus (i.e., it can remove HBV DNA and / or HBsAg in the body, remove HBV in the body and cells infected by HBV), so as to have great clinical value.

[0102] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art, and include but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); bacteriophages such as lambda phage or M13 phage and animal viruses, etc. Animal viruses that can be used as vectors include but are not limited to retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses (such as SV40). A vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may also contain a replication initiation site.

[0103] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.

[0104] As used herein, the term "identity" is used to refer to the matching of sequences between two polypeptides or between two nucleic acids. When a position in both sequences being compared is occupied by the same base or amino acid monomer subunit (e.g., a position in each of the two DNA molecules is occupied by adenine, or a position in each of the two polypeptides is occupied by lysine), then the molecules are identical at that position. The "percent identity" between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions being compared x 100. For example, if 6 out of 10 positions in two sequences match, then the two sequences have 60% identity. For example, the DNA sequences CTGACT and CAGGTT share 50% identity (3 out of a total of 6 positions match). Typically, two sequences are compared when they are aligned to produce maximum identity. Such an alignment can be achieved by using, for example, the method of Needleman et al. (1970) J. Mol. Biol. 48: 443-453, which can be conveniently performed by a computer program such as the Align program (DNAstar, Inc.). The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl Biosci., 4: 11-17 (1988)), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J MoI Biol. 48: 444-453 (1970)) algorithm, which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using a Blossum 62 matrix or a PAM250 matrix and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

[0105] The compilation of the twenty conventional amino acids involved in this article follows conventional usage. See, for example, Immunology-A Synthesis (2nd Edition, ES Golub and DR Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. And in the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0106] As used herein, the term "pharmaceutically acceptable carrier and / or excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with a subject and an active ingredient, which is well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH regulators, surfactants, adjuvants, ionic strength enhancers, diluents, agents that maintain osmotic pressure, agents that delay absorption, and preservatives. For example, pH regulators include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. Agents that maintain osmotic pressure include, but are not limited to, sugars, NaCl, and the like. Agents that delay absorption include, but are not limited to, monostearate and gelatin.

[0107] As used herein, the term "prevention" refers to a method implemented in order to prevent or delay the occurrence of a disease or condition or symptom (e.g., HBV infection or a disease associated with HBV infection) in a subject. As used herein, the term "treatment" refers to a method implemented in order to obtain a beneficial or desired clinical result. For the purposes of the present invention, beneficial or desired clinical results include (but are not limited to) alleviating symptoms, reducing the scope of the disease, stabilizing (i.e., no longer worsening) the state of the disease, delaying or slowing the development of the disease, improving or alleviating the state of the disease, and alleviating symptoms (whether partially or completely), whether detectable or undetectable. In addition, "treatment" can also refer to prolonging the survival period compared to the expected survival period (if not treated). In the present application, the antibodies of the present invention have the ability to neutralize HBV, so that they can be used to prevent / prevent non-diseased subjects or their cells from being infected with HBV. In addition, the antibodies of the present invention have the ability to remove HBV (i.e., they can remove HBV DNA and / or HBsAg in the body, remove HBV and cells infected by HBV in the body), so that they can be used to treat HBV infection in diseased subjects or diseases associated with HBV infection.

[0108] As used herein, the term "subject" refers to a mammal, such as a primate mammal, such as a human.

[0109] As used herein, the term "effective amount" refers to an amount sufficient to obtain or at least partially obtain the desired effect. For example, an effective amount for preventing a disease (such as HBV infection or a disease associated with HBV infection) refers to an amount sufficient to prevent, prevent, or delay the occurrence of a disease (such as HBV infection or a disease associated with HBV infection); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially prevent the disease and its complications in a patient who already has the disease. Determining such an effective amount is entirely within the capabilities of those skilled in the art. For example, an effective amount for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition such as age, weight and gender, the mode of administration of the drug, and other treatments administered simultaneously, etc.

[0110] The invention will now be described with reference to the following examples which are intended to illustrate the invention rather than to limit the invention.

[0111] Those skilled in the art will appreciate that the embodiments describe the present invention by way of example and are not intended to limit the scope of protection claimed in the present application. The experimental methods in the embodiments are conventional methods unless otherwise specified. If specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially.

[0112] Example 1. Screening of Fc point mutations that enhance phagocytosis of hepatitis B virus antigen by humanized heavy chain antibody h125S-26-mediated human phagocytes

[0113] 1.1H125S-26 antibody variable region sequence

[0114] The anti-HBsAg humanized heavy chain antibody h125s-26 (described in detail in Chinese patent application PCT No.: PCT / CN2023 / 073343) developed in the early stage of the laboratory was used as the parent antibody, and its heavy chain constant region was Fc engineered to maintain its variable region sequence and corresponding HBsAg binding characteristics. The antibody molecule h125s-26 obtained after humanization maintained the HBsAg binding activity and in vivo therapeutic effect equivalent to the parent. Its variable region sequence is shown in Table 1.

[0115] Table 1. Amino acid sequence of the variable region of humanized heavy chain antibody h125S-26

[0116]

[0117] Table 2. Amino acid sequences of CDRs and FRs of humanized heavy chain antibody h125s-26

[0118]

[0119] 1.2 Design of Fc point mutations to enhance antibody-mediated phagocytosis of HBV antigens by human phagocytes

[0120] Antibodies can interact with FcγRs on the surface of phagocytes through Fc, mediating the antibody-dependent cellular phagocytosis (ADCP) effect to achieve specific viral antigen clearance. In order to enhance the phagocytosis of hepatitis B virus antigens mediated by h125s-26 antibody on human phagocytes and enhance the affinity with human FcγRs (hFcγRs), different point mutation combinations were introduced into its Fc domain, including S239D / A330L / I332E (SDALIE) and G236A / S239D / A330L / I332E (GASDALIE). The constant region sequences of the mutant antibodies are shown in Table 3.

[0121] Table 3. Heavy chain constant region sequences of Fc mutant antibodies targeting hFcγRs

[0122]

[0123]

[0124] 1.3 Preparation of Fc mutant antibodies with enhanced binding to hFcγRs

[0125] 1.3.1 Construction of antibody expression vector

[0126] The gene sequence encoding the variable region of the nanobody was constructed into the PTT5-H vector containing the heavy chain constant region (Hinge-CH2-CH3) sequence of the Fc mutant. The construction of the recombinant expression vector was entrusted to General Bio (Anhui) Co., Ltd. The recombinant vector was transformed into DH5α competent cells (Shenzhen Kangti), and after growing on an ampicillin-resistant LB plate for 12 hours, a single clone was picked and sent for sequencing (Shanghai Biotech). The recombinant plasmid with correct sequencing was extracted in large quantities using an endotoxin-free plasmid extraction kit (TianGen, DP117).

[0127] 1.3.2 Eukaryotic expression and purification of antibodies

[0128] Use a single plasmid to transiently transfect Expi-293F cells to express antibodies. Prepare Expi-293F cells with a viability of more than 95% and culture at a volume of 4 × 10 6Take 200mL of the density and inoculate it in a 1L cell culture flask. Take 1mg of the heavy chain recombinant plasmid and mix it with 2mg PEI. After vigorous shaking for 8s, let it stand for 8min, and add the mixture to 200mL of cells. After 4h, add 200mL of Freestyle medium and place it in a 5% CO2 incubator at 37℃ for 7 days. Collect the cell supernatant, centrifuge it at 10000rpm for 30min, take the supernatant and perform subsequent purification.

[0129] Filter the cell supernatant with a 0.22 μm filter; turn on the AKTA instrument, first rinse the A and B pipes with A solution (200 mM sodium hydrogen phosphate dodecahydrate) and B solution (100 mM citric acid monohydrate), and install the protein A column; use A solution to balance the protein A column for more than 15 minutes at a flow rate of 8 mL / min, and proceed to the next step after the UV value, pH value and conductivity detected by the instrument are stable; load the sample at a flow rate of 6-10 mL / min, then the UV value will rise, and this peak is the penetration peak, and continue to wash the column with A solution, and collect the penetration peak sample for detection. After the pH value no longer changes, use B solution at a flow rate of 6-10 mL / min, then the pH value drops, the UV value rises, and this peak is the elution peak. The antibody is mainly present in the elution peak, and the elution peak sample is collected for detection; balance the column with A solution, and then fill the pipe and protein A column with 20% ethanol, remove the column, and store at 4°C. The purified monoclonal antibody was dialyzed against 20 mM PBS buffer overnight, and the concentration was measured by UV spectrometry or BCA, dispensed into 1.5 mL tubes, and stored at -20°C for later use.

[0130] 1.4 Screening of Fc mutant antibodies with enhanced binding to hFcγRs

[0131] 1.4.1 The affinity of two Fc mutant antibodies to various hFcγRs was determined by surface plasmon resonance (SPR) technology. SPR experiments were performed on a BIAcore 8K (GE Healthcare, USA) at 25°C in HBS-EP+ (Cytiva, USA) buffer. Human FcγRs were purchased from Beijing Sino-Biological, and the C-terminus of hFcγRs was fused with a 6×His tag. Briefly, antibodies were immobilized on a ProteinA sensor chip (GE Healthcare, USA) at a density of 300 reaction units (RU). Serial dilutions of recombinant hFcγRs were injected into the flow cell at a rate of 30 μL / min, ranging from 400 to 3.125 nM (1:2 serial dilution). The binding time was 90 seconds, followed by a 120-second dissociation step. At the end of each cycle, the sensor surface was regenerated by glycine hydrochloride buffer (10 mM, pH 1.7; 50 μL / min, 30 s). KD values ​​were calculated using BIAcore 8K evaluation software (GE Healthcare, USA) with a 1:1 Langmuir binding model.

[0132] The results are shown in Table 4. After the introduction of point mutations in Fc, h125s-26-SDALIE and h125s-26-GASDALIE enhanced their affinity to various human FcγRs to varying degrees compared to the antibody h125s-26 with wild-type Fc. The affinity of h125s-26-SDALIE to hFcγRIIIa and hFcγRIIIb increased by 6.47 and 21.23 times, respectively, but the affinity to hFcγRIIa decreased by 0.55 times. The affinity of h125s-26-GASDALIE to hFcγRIIa, hFcγRIIIa and hFcγRIIIb increased by 2.45, 1.11 and 4.08 times, respectively.

[0133] Table 4. SPR determination of the affinity of antibodies to different human FcγRs

[0134]

[0135] 1.4.2 In order to evaluate the ADCP effect mediated by antibodies in human phagocytes, freshly isolated human peripheral blood was selected as the phagocytic evaluation system, which contains a variety of phagocytes such as monocytes, neutrophils and dendritic cells (DC).

[0136] 1600ng / mL Dylight 488-HBsAg was mixed with 5μg / mL and 0.1μg / mL of the test antibody in RPMI-1640 buffer in equal volumes (150μL:150μL) and incubated at 37°C for 1h. 250μL of the mixture was added to 250μL of freshly isolated human peripheral blood (peripheral blood was collected in an anticoagulant tube containing EDTA; from 4 blood donors) and incubated at 37°C for 2h. Peripheral blood was treated with 3-4mL of red blood cell lysis buffer (Beijing Solebow Technology Co., Ltd.) at room temperature for 15-30min until there was no obvious red precipitate. Centrifuge at 1800rpm for 10min, and the cell pellet was washed twice with PBS. Cells were stained at 4°C for 30min using anti-human CD45, F4 / 80, CD11c, CD14, and Ly-6G fluorescent antibodies with different fluorescent labels (not Dylight488). The cells were washed once with PBS and passed through a cell screen with a pore size of 70 μm for flow cytometry analysis. The human immune cells (Leukocyte), neutrophils, monocytes and DC cell populations were determined by flow cytometry gating strategy. The proportion of Dylight488 positive cells (HBsAg+) and the mean fluorescence intensity (MFI) in different phagocyte populations were counted to analyze the antibody-mediated HBsAg phagocytosis efficiency.

[0137] The results are as follows Figure 1 As shown in Table 5, compared with the parent antibody h125s-26, both Fc mutant antibodies can mediate significantly enhanced viral antigen phagocytosis efficiency (manifested as significantly improved antigen MFI and HBsAg+) in the total population of human peripheral blood immune cells, among which h125s-26-GASDALIE mediated the highest phagocytosis efficiency. At the same time, h125s-26-GASDALIE can also cause the strongest ADCP effect in neutrophils, monocytes and DCs. h125s-26-GASDALIE is superior to h125s-26-SDALIE in terms of MFI of total leukocytes and various immune cells and the multiple change of HBsAg+ positive cell rate.

[0138] Table 5. Fc mutant antibody-mediated MFI and HBsAg+ positive cell rate change fold

[0139]

[0140] Example 2. Screening of Fc double mutation combinations that simultaneously enhance ADCP effect and extend antibody half-life

[0141] 2.1 Design of Fc double mutation combination to enhance ADCP effect and prolong antibody half-life

[0142] In order to further extend the half-life of the h125s-26-GASDALIE antibody, point mutations M428L / N434S (h125s-26-GASDALIE-LS) and T307Q / N434S (h125s-26-GASDALIE-LS-QS) that can enhance binding to human FcRn (hFcRn) at acidic pH were introduced into its Fc domain. The constant region sequences of the two Fc double mutant antibodies are shown in Table 6.

[0143] Table 6. Heavy chain constant region sequences of Fc double mutant antibodies

[0144]

[0145] 2.2 Preparation of Fc double mutant antibodies

[0146] The Fc double mutant antibody was eukaryotically expressed and purified using the same method as in Example 1.3.

[0147] 2.3 Screening of Fc double mutant antibodies

[0148] 2.3.1 Verification of affinity of Fc double mutant antibodies to hFcRn under acidic pH conditions

[0149] The binding activity of the Fc double mutant antibody to hFcRn was evaluated using the previously constructed MDCK cell line that can stably display hFcRn on the membrane (Kang, C., L. Xia, Y. Chen, T. Zhang, Y. Wang, B. Zhou, M. You, Q. Yuan, C. M. Zeng, Z. An, W. Luo, N. Xia, Protein Cell 2018. 9(1): p. 130-134.).

[0150] After trypsin digestion of hFcRn-MDCK stable transfected cells, the cells were counted and dispensed into sterile 96-well cell plates, with 5×10 cells per well. 5. Antibodies were diluted with PBS containing 1% BSA, pH 6.0, 1 μg / μL in the first well, and then diluted 3 times in a 96-well microplate. The plate with cells was centrifuged, the supernatant was aspirated, and then centrifuged and washed twice with PBS (1% BSA) at pH 6.0, then 100 μL of the diluted antibody and 1 μg Dylight 650-human IgG (SIGMA-ALDRICH, USA) were added, resuspended and mixed, incubated at 4°C in the dark for 1 hour, and finally centrifuged and washed twice with PBS (1% BSA) at pH 6.0 and resuspended for flow analysis. Empty cells resuspended with pH 6.0 PBS were used as negative controls, and cells with only Dylight 650-human IgG were used as positive controls. The mean fluorescence intensity (gMFI) of Dylight 650 on the cell surface was counted by flow cytometry. The blocking rate was calculated according to the following formula: 1-(gMFI of positive control group-gMFI of experimental group) / gMFI of positive control group×100%.

[0151] The results are as follows Figure 2 As shown, the IC values ​​of h125s-26 and h125s-26-GASDALIE antibodies without FcRn point mutations were compared with hFcRn. 50 The efficiency of the Fc double mutant antibody h125s-26-GASDALIE-QS in blocking human IgG binding to hFcRn was significantly improved, IC 50 It was 30.17 μg / mL, indicating that the binding activity of h125s-26-GASDALIE-QS to hFcRn was significantly enhanced at acidic pH.

[0152] 2.3.2 Verification of ADCP effect mediated by Fc double mutant antibody in human phagocytes

[0153] The same method as in Example 1.4.2 was used to evaluate whether the antibody introduced with the Fc double mutation combination could still maintain the enhanced ADCP effect in freshly isolated human peripheral blood.

[0154] The results are as follows Figure 3 As shown in Table 7, compared with antibody h125s-26-GASDALIE, the antibody-mediated ADCP efficiency was further improved after the introduction of the Fc point mutation QS with enhanced affinity for hFcRn, and further enhanced ADCP effect could also be mediated in neutrophils, monocytes and DCs.

[0155] Table 7. Fc double mutant antibody-mediated MFI and HBsAg+ positive cell rate change fold

[0156]

[0157] Thus, an engineered hepatitis B therapeutic antibody h125s-26-GASDALIE-QS with a high degree of humanization and enhanced Fc-hFcγRs and Fc-hFcRn interactions was designed. Figure 4 shown.

[0158] Example 3. Identification of in vitro properties of h125s-26-GASDALIE-QS

[0159] 3.1 Identification of Antibody Properties by Reducing SDS-PAGE

[0160] Using SurePAGE TM ,Bis-Tris,10×8,4~20%,15wells” precast gel (Nanjing GenScript Biotechnology Co., Ltd.), loaded into the electrophoresis tank, and diluted protein electrophoresis buffer was added between the electrophoresis tanks. According to the antibody concentration, 3~5μg of antibody was taken into a 1.5mL EP tube, PBS buffer was added to the final volume of 10μL, 2μL of reducing buffer was added and the metal bath was 100℃ for 10min, and then the sample was added to the precast gel in the electrophoresis tank, the voltage was 150V, and the gel was removed after running, and the eStainL1 protein stainer was used for rapid Coomassie brilliant blue staining and decolorization, and then the gel imaging was completed.

[0161] The results are as follows Figure 5 As shown, the purified engineered antibody has a single band with a molecular weight between 40-55kDa, which is relatively pure. Humanization and Fc engineering transformation do not affect the expression and band size of the antibody, and the antibody properties are uniform, which is conducive to industrial production.

[0162] 3.2 Detection of antibody binding ability to HBsAg by ELISA

[0163] First, the concentration of the purified antibody was determined using a BCA protein quantification kit, and the antibody concentration was uniformly diluted to 10 μg / mL. Subsequently, the antibody concentration was gradiently diluted 3 times with 20% NBS, for a total of 9 concentration gradients. Subsequently, the diluted antibody was added to a commercial HBsAg plate (purchased from Beijing Wantai) and incubated at 37°C for 1 hour. Subsequently, the ELISA plate was washed 5 times with PBST and dried. Subsequently, the GAH-HRP enzyme-labeled secondary antibody was added, incubated for 30 minutes, the plate was washed 5 times with PBST, and dried. And the substrate TMB solution was added. After 15 minutes of color development, the color development reaction was terminated with H2SO4, and the reading was measured at OD450 / 630.

[0164] The results are as follows Figure 6As shown, h125s-26-GASDALIE-QS has good HBsAg binding activity, EC 50 The EC of the parent h125s-26 was 124.1 ng / mL, which was comparable to that of the parent h125s-26. 50 The value indicated that Fc engineering modification did not affect the binding activity of the antibody to HBsAg.

[0165] Example 4. Pharmacodynamic evaluation of h125s-26-GASDALIE-QS antibody in hFcγRs transgenic mice

[0166] 4.1 In this example, in order to evaluate the in vivo therapeutic effect of h125s-26-GASDALIE-QS in the HBV-infected mouse model and verify the Fc engineering effect of hFcγRs affinity enhancement, 4-week-old hFcγRs transgenic mice (hFcγRs-Tg, purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.) were used to culture 1×10 11 vg / mouse was injected with rAAV-HBV adeno-associated virus (adr serotype, purchased from Guangzhou Paizhen Biotechnology Co., Ltd.) through the tail vein, and blood was collected for four consecutive weeks to monitor the virus titer of mice. After the virus titer stabilized, h125s-26 and h125s-26-GASDALIE-QS at a dose of 5 mg / kg were injected into the mice by intraperitoneal administration (5 mice per group). Blood was collected from the orbital venous plexus of mice 3 days before antibody administration, on the day of administration, and on days 1, 3, 5, 7, 9, 12, and 16 after administration, and serum was collected by centrifugation at 12000rpm. HBsAg in serum was uniformly tested after the experiment.

[0167] 4.2 Quantitative detection of HBsAg

[0168] (1) Preparation of reaction plate: HBsAg quantitative detection kit was purchased from Beijing Wantai Biopharmaceutical Co., Ltd., and the chemiluminescent reaction plate therein was used.

[0169] (2) Sample dilution: The collected mouse serum was diluted with ED-11 solution at a ratio of 1:50 for subsequent quantitative detection. The HBsAg standard was diluted with ED-11 solution to 45 IU / mL, and then diluted 5-fold for a total of 6 dilution gradients;

[0170] (3) Sample reaction: The diluted samples and standards were added to the chemiluminescent plate at 100 μL / well and reacted at 37°C for 1 h.

[0171] (4) Enzyme labeling reaction: Add 50 μL / well of the enzyme-labeled secondary antibody dilution in the kit to the chemiluminescent plate and react at 37°C for 1 h. Then wash the plate 5 times with PBST and spin dry.

[0172] (5) Luminescent reaction and measurement: Add luminescent solution (100 μL / well) to the chemiluminescent plate and perform light intensity detection.

[0173] (6) Calculation of HBsAg concentration in mouse serum samples: A standard curve was drawn based on the measurement results of the standard sample. Then, the light intensity measurement value of the mouse serum sample was substituted into the standard curve to calculate the HBsAg concentration in the serum sample to be tested.

[0174] 4.3 Results Figure 7 As shown, in this mouse model, h125s-26 caused a rapid decrease in the serum HBsAg titer of mice 1 day after administration, but it did not drop to the detection limit, and the HBsAg titer rebounded rapidly after 1 day. In contrast, h125s-26-GASDALIE-QS can reduce the serum HBsAg titer of mice to the detection limit after treatment, and maintain it at the detection limit for up to 5 days, and rebound to the baseline level after 9 days of treatment. In this treatment model, h125s-26-GASDALIE-QS showed a stronger serum antigen clearance effect than the parent antibody h125s-26 in a high HBsAg background. This significantly enhanced efficacy reflects the effect of the Fc domain to enhance the affinity modification of hFcγRs.

[0175] Example 5. Evaluation of the antibody half-life of h125s-26-GASDALIE-QS in hFcRn transgenic mice

[0176] 5.1 Based on the enhanced binding activity of h125s-26-GASDALIE-QS to hFcRn at acidic pH observed in Example 2, the half-life of the antibody in serum was further verified in hFcRn transgenic (hFcRn-Tg) mice.

[0177] This experiment used 4-week-old hFcRn-Tg mice purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd. H125s-26 and h125s-26-GASDALIE-QS at a dose of 5 mg / kg were injected into the mice by tail vein (iv) (4 mice per group). Blood was collected from the orbital venous plexus of the mice on days 1, 2, 5, 7, 9, 12, 14, 17, 20, 23, 26, 28 and 30 after antibody administration, and serum was collected by centrifugation at 12000 rpm. The half-life of the antibody in vivo was analyzed by detecting the antibody concentration in the serum.

[0178] 5.2 Quantitative detection of antibody concentration

[0179] (1) Preparation of reaction plate: Dilute goat anti-human Fab domain-specific antibody (I5260-1ML; SIGMA-ALDRICH, USA) to 2 μg / mL with 20 mM PB buffer (Na2HPO4 / NaH2PO4 buffer, pH 7.4), add 100 μL of coating solution to each well of the ELISA plate, and coat at 2-8°C for 16-24 h, then coat at 37°C for 2 h, wash the plate once with PBST washing solution, and spin dry. After washing, add 200 μL of blocking solution to each well, and block at 37°C for 2 h. Then, discard the blocking solution, put the plate in a drying room to dry, and store at 2-8°C for future use.

[0180] (2) Sample dilution: The collected mouse serum was diluted with PBS solution into two gradients of 1:200 and 1:1000 for subsequent quantitative detection. The standard was commercial human IgG (IgG from human serum, I4506-10MG) diluted in gradients. The first well was 5 μg / mL, 2-fold gradient dilution, and a total of 12 gradients.

[0181] (3) Sample reaction: The diluted samples and standards were added to the blocked ELISA plate at 100 μL / well and reacted at 37°C for 1 h. The reaction plate was then washed 5 times with PBST and dried.

[0182] (4) Enzyme marker reaction: Add 100 μL / well of goat anti-human Fc antibody diluted 1:5000 with ED-11 to the ELISA plate and react at 37°C for 1 h. Then wash the plate 5 times with PBST and spin dry.

[0183] (5) Luminescent reaction and measurement: Luminescent solution (100 μL / well) was added to the ELISA plate, and stop solution (50 μL / well) was added after 15 minutes, and light intensity was detected.

[0184] (6) Calculation of antibody concentration in mouse serum samples: A standard curve is drawn based on the measurement results of the standard sample. Then, the light intensity measurement value of the mouse serum sample is substituted into the standard curve to calculate the antibody concentration in the serum sample to be tested.

[0185] 5.3 Results Figure 8As shown, compared with the concentration of antibodies in serum, the half-life of h125s-26-GASDALIE-QS is significantly longer than that of the parent antibody h125s-26. The half-life of h125s-26 in this mouse evaluation model is about 5 days, and the antibody is completely cleared on the 20th day. The half-life of the Fc-modified antibody h125s-26-GASDALIE-QS is about 7 days, and the antibody is completely cleared on the 30th day. In this evaluation model, the half-life and complete clearance time of the h125s-26-GASDALIE-QS antibody are significantly longer than those of the parent antibody h125s-26, reflecting the effect of the Fc domain enhancing the affinity modification of hFcRn. The in vivo pharmacokinetic data are consistent with the in vitro hFcRn affinity data observed in Example 2.

[0186] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Anti-HBV antibodies, comprising an antigen binding domain and an Fc domain, in, The heavy chain CDR1 to 3 of the antigen binding domain have the amino acid sequences shown in SEQ ID NOs: 6 to 8, respectively. Alternatively, its CDR region has a sequence in which one or more amino acids are substituted, deleted, added and / or replaced based on the amino acid sequence shown above; or has a sequence with an identity of more than 80% with the amino acid sequence shown in any of the preceding items; The Fc domain comprises a first mutation that enhances binding to hFcγRs and a second mutation that enhances binding to hFcRn.

2. The antibody according to claim 1, wherein The first mutation at least enhances binding to hFcγRIIIb; Preferably, the first mutation also enhances binding to hFcγRIIa and / or hFcγRIIIa; Preferably, the first mutation is selected from the following mutations according to EU numbering: S239D / A330L / I332E, G236A / S239D / A330L / I332E.

3. The antibody according to any one of claims 1 to 2, wherein The first mutation is G236A / S239D / A330L / I332E.

4. The antibody according to any one of claims 1 to 3, wherein The second mutation is selected from the following mutations according to EU numbering: M428L / N434S, T307Q / N434S; Preferably, the second mutation is T307Q / N434S.

5. The antibody according to any one of claims 1 to 4, wherein The first mutation is S239D / A330L / I332E, and the second mutation is T307Q / N434S.

6. The antibody according to any one of claims 1 to 5, wherein The Fc domain is IgG, such as IgG1, IgG2, IgG3, or IgG4; Preferably, the Fc domain is human IgG1.

7. The antibody according to any one of claims 1 to 6, wherein The antibody comprises a heavy chain constant region (CH) shown in any one of SEQ ID NOs: 9-13; Preferably, the antibody comprises a heavy chain constant region (CH) shown in SEQ ID NO:

13.

8. The antibody according to claims 1-7, wherein The antigen binding domain comprises: a heavy chain variable region (VHH) comprising the sequence shown in SEQ ID NO: 1 or a sequence having at least 80% identity thereto.

9. The antibody according to any one of claims 1 to 8, comprising: a heavy chain comprising a VHH as shown in SEQ ID NO: 1 and a CH as shown in any one of SEQ ID NOs: 9 to 13; Preferably, the antibody comprises: a heavy chain including VHH shown in SEQ ID NO:1 and CH shown in SEQ ID NO:

13.

10. Biological material, comprising any one of the following a) to h): a), a nucleic acid encoding the antibody according to any one of claims 1 to 9; b), an expression unit comprising a promoter and the nucleic acid described in a); c) a plasmid vector containing the nucleic acid described in a) or the expression unit described in b); d) a host, in whose genome the nucleic acid described in a) or the expression unit described in b) is integrated, or the plasmid vector described in c) is transformed or transfected; e), a labeled antibody, comprising the antibody according to any one of claims 1 to 4 and a labeling substance; f), a conjugate comprising the antibody according to any one of claims 1 to 4 and a medium; g) a multispecific antibody comprising the antibody according to any one of claims 1 to 9 and a fragment that specifically binds to other targets; h) An antibody derivative, which comprises the antibody according to any one of claims 1 to 9 and a drug for preventing and treating hepatitis B.

11. The biomaterial according to claim 10, characterized in that In the labeled antibody, the labeling substance is a chemical label or a biological label; In the conjugate, the medium is selected from colloidal gold, ELISA plate, magnetic beads or latex microspheres; The multispecific antibody is a bispecific antibody or a trispecific antibody; Among the antibody derivatives, the drug for preventing and treating hepatitis B is a protein drug.

12. A method for preparing the antibody according to any one of claims 1 to 9, comprising: Cultivate the host according to claim 5 to obtain a culture containing the antibody.

13. Use of at least one of the antibodies according to any one of claims 1 to 9 or the biological materials according to claim 10 or 11 in the preparation of a product for detecting hepatitis B virus.

14. A product for detecting hepatitis B virus, wherein the raw materials for preparing the product include at least one of the antibody according to any one of claims 1 to 9 or the biological material according to claim 10 or 11 and an immunological detection reagent.

15. A method for detecting hepatitis B virus for non-diagnostic purposes, comprising detecting a sample with the product of claim 14.

16. Use of at least one of the antibodies according to any one of claims 1 to 9 or the biomaterials according to claim 10 or 11 in the preparation of products for preventing and treating diseases caused by hepatitis B virus infection.

17. A product for preventing and treating diseases caused by hepatitis B virus infection, wherein the raw materials for its preparation include at least one of the antibodies according to any one of claims 1 to 9 or the biological materials according to claim 10 or 11 and auxiliary materials.

18. The product according to claim 17, characterized in that This also includes other drugs that have activity in preventing and treating diseases caused by hepatitis B virus infection.

Citation Information

Patent Citations

  • Medicine for preventing and curing allergic diseases of fusion protein based on TIM protein and IgG protein and preparation method thereof

    CN108245685A

  • HIV antibody derivatives with dual antiviral and immunomodulatory activity

    CN108699131A

  • Epitope peptide and antibody for treating HBV infection and related diseases

    CN116496389A

  • Anti-hepatitis B virus antibody and preparation and application thereof

    CN117304308A